Biosimilar Developers Can Breathe a Sigh of Relief

more+
less-

With this morning’s Supreme Court affirmance of the bulk of the Affordable Care Act, the specter that the BPCIA framework for biosimilar introduction could be dismantled is no longer a concern.  Presumably it will be full speed ahead through the regulatory process, and we will see biosimilar applications for approval and attendant patent litigation before too long.  It will be years, though, before there will be sufficient experience to assess whether the BPCIA will achieve its goals of spurring competition for important biologics without undermining the incentives for new innovations.  In the meantime, one wonders whether there will be appetite among the stakeholders for preemptively amending the Act (for example, by changing the 12 year exclusivity period) when the firestorm over changing or repealing the ACA begins in the next Congress.

 

Published In: Administrative Agency Updates, Elections & Politics Updates, Intellectual Property Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Dechert LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »